FA
CRSP icon

FDx Advisors’s CRISPR Therapeutics CRSP Stock Holding History

FDx Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-6,766
Closed -$424K – 411
2023
Q4 		$424K Buy
6,766
+438
+7% +$24.2K 0.03% 428
2023
Q3 		$287K Sell
6,328
-1,749
-22% -$90.3K 0.02% 489
2023
Q2 		$453K Sell
8,077
-130
-2% -$7.38K 0.02% 472
2023
Q1 		$334K Hold
8,207
– – 0.01% 534
2022
Q4 		$334K Sell
8,207
-1,816
-18% -$96.3K 0.01% 534
2022
Q3 		$655K Sell
10,023
-472
-4% -$34.2K 0.03% 360
2022
Q2 		$638K Buy
10,495
+1,897
+22% +$112K 0.02% 412
2022
Q1 		$540K Buy
8,598
+1,500
+21% +$94.2K 0.02% 483
2021
Q4 		$538K Buy
7,098
+1,013
+17% +$88.5K 0.01% 509
2021
Q3 		$681K Buy
6,085
+327
+6% +$41.1K 0.02% 419
2021
Q2 		$932K Sell
5,758
-1,255
-18% -$153K 0.03% 351
2021
Q1 		$855K Sell
7,013
-2,122
-23% -$320K 0.03% 330
2020
Q4 		$1.4M Buy
9,135
+240
+3% +$28.4K 0.06% 213
2020
Q3 		$744K Buy
8,895
+4,008
+82% +$356K 0.03% 286
2020
Q2 		$359K Buy
+4,887
New +$286K 0.02% 404

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FDx Advisors's CRSP Position: Q1 2024 in Review

FDx Advisors sold out of CRISPR Therapeutics (CRSP) in Q1 2024, closing a stake of 6,766 shares — an estimated $424K sold.

FDx Advisors first reported a position in CRSP in Q2 2020 and held it in 15 quarters. The position peaked at $1.4M in Q4 2020. 484 funds tracked by Wall St. Rank hold CRSP as of Q1 2024.

  • FDx Advisors reported no remaining CRISPR Therapeutics position as of Q1 2024 after selling out during the quarter.
  • FDx Advisors sold 6,766 CRISPR Therapeutics shares in Q1 2024, an estimated $424K.
  • FDx Advisors first reported a position in CRISPR Therapeutics in Q2 2020 and held it in 15 quarters.
  • FDx Advisors's CRISPR Therapeutics position peaked at $1.4M in Q4 2020.
  • 484 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2024.

Based on FDx Advisors's 13F filing for Q1 2024, filed 3 May 2024.